Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 678-683

  Malcolm, R Karl ^a   Forbes, Claire J ^a   Geer, Leslie ^b   Veazey, Ronald S ^c   Goldman, Laurie ^b   Klasse, Per Johan ^d   Moore, John P ^d  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Particle Sciences   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Drug delivery; HIV; Vaginal microbicide

Indexed keywords

HYDROXYETHYLCELLULOSE; MARAVIROC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GEL; NONHUMAN; RHESUS MONKEY; SINGLE DRUG DOSE; VAGINA DISCHARGE;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; BODY FLUIDS; CYCLOHEXANES; FEMALE; HIV FUSION INHIBITORS; MACACA MULATTA; PLASMA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TIME FACTORS; TRIAZOLES; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84873580295     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks422     Document Type: Article

References (30)

1. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59: 455-71.
2. Hendrix CW, Cao YJ, Fuchs EJ. Topical microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol 2010: 49: 349-75.
3. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2012; 2: a007385.
4. Woolfson AD, Malcolm RK, Toner CF et al. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: a controlled-release strategy for HIV microbicides. Am J Drug Deliv 2006; 4: 7-20.
5. Malcolm RK, Veazey RS, Geer L et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012; 56: 2251-8.
6. Nel A, Smythe S, Young K et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 416-23.
7. Romano R, Variano B, Coplan P et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Human Retroviruses 2009; 25: 483-8.
8. Johnson TJ, Gupta KM, Fabian J et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010; 39: 203-12.
9. Malcolm RK, Edwards K-L, Kiser P et al. Advances in microbicide vaginal rings. Antiviral Res 2010; 88: S30-9.
10. Johnson TF, Srinivasan P, Albright TH et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2012; 56: 1291-99.
11. Mesquita PMM, Rastogi R, Segarra TJ et al. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother 2012; 67: 1730-8.
12. Nel AM, Coplan P, van de Wijgert JH et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009; 23: 1531-8.
13. Tsibris AMN, Pal U, Schure AL et al. SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One 2011; 6: e28047.
14. Veazey RS, Ketas TJ, Dufour J et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010; 202: 739-44.
15. Van Damme L, Ramjee G, Alary M et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360: 971-7.
16. Schwartz JL, Rountree W, Kashuba ADM et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011; 6: e25974.
17. Karim QA, Karim SSA, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329: 1168-74.
18. Acartürk F. Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 2009; 3: 193-205.
19. AndrewsGP, Donnelly L, JonesDS et al. Characterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery. Biomacromolecules 2009; 10: 2427-35.
20. Forbes CJ, Lowry D, Geer L et al. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 2011; 156: 161-9.
21. Veazey RS, Klasse PJ, Schader SM et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438: 99-102.
22. Veazey RS, Springer MS, Marx PA et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005; 11: 1293-4.
23. Neff CP, Kurisu T, Ndolo T et al. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 2011; 6: e20209
24. Brouwers J, Vermeire K, Grammen C et al. Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: a case study with saquinavir. Antiviral Res 2011; 91: 217-23.
25. Rustomjee R, Abdool Karim Q, Abdool Karim SS et al. Phase I trial of nonoxynol-9 film among sex workers in South Africa. AIDS 1999; 13: 1511-5.
26. Stafford MK, Ward H, Flanagan A et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 327-31.
27. Rosario MC, Jacqmin P, Dorr P et al. A pharmacokineticpharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther 2005; 78: 508-19.
28. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
29. Dumond J, Patterson KB, Pecha AL et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 546-53.
30. Walker DK, Abel S, Comby P et al. Species differences in the disposition of the CCR5 antagonist, UK- 427,857, a new potential treatment for HIV. Drug Metab Dispos 2005; 33: 587-95.